Muscular Dystrophy Association: MDA Venture Philanthropy Program

The Muscular Dystrophy Association (MDA) is accepting Letters of Intent (LOIs) from small pharmaceutical and biotech companies and academics developing treatments and therapies for neuromuscular diseases. Companies may be public or private, in industry or in academia, and located in the U.S. or internationally. MVP funds academic investigators doing appropriate studies, but encourages corporate collaboration. Award amount varies. The LOI deadline is March 1, 2017.

The Office of Corporate and Foundation Relations has identified the following private funding opportunity:

Muscular Dystrophy Association: MDA Venture Philanthropy Program
http://www.mda.org

The Muscular Dystrophy Association (MDA) is accepting Letters of Intent (LOIs) from small pharmaceutical and biotech companies and academics developing treatments and therapies for neuromuscular diseases. Companies may be public or private, in industry or in academia, and located in the U.S. or internationally. MVP funds academic investigators doing appropriate studies, but encourages corporate collaboration. MVP supports projects in any of the more than 40 neuromuscular diseases as outlined on mda.org. MVP funds projects from proof of principle in an animal model through Phase II trials. Projects may include toxicology, manufacturing and scale-up, pre-IND, Phase I or early Phase II trials. MVP will consider funding projects up to $3M, depending on the stage of research. MVP is interested in partnering with applicants to accelerate research on projects with strong institutional support, and in general MVP funds should constitute less than 50% of the total project budget. The award period will be on average 2 years, but follow-on investment may be negotiated if all milestones are met and the project moves into later phases of development. MVP acknowledges that drug development is a long process, and that the horizon for drug approval may be up to ten years after MVP investment. Research and Development awards may be up to $500,000; Preclinical awards may be up to $1,000,000; and, Early Clinical (Phase I/II) may be up to $3,000,000.

LOI Deadline: March 1, 2017. Application Guidelines for the award: https://www.mda.org/sites/all/themes/mda_bootstrap_subtheme/pdf/MVP-APP-INSTRUCTIONS-2016.pdf

The UNC Office of Corporate and Foundation Relations is available to provide assistance in pursuing privately funded opportunities. If you have any questions about this funding opportunity, please email cfr@unc.edu or phone 919.962.2867.

Filed under: